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The androgen receptor inhibitor, Enzalutamide, proved effective against castration resistance prostate cancer, has
demonstrated clinical benefits and increased survival rate in men. However, AR mutation (F876L) converts
Enzalutamide from antagonist to agonist indicating a rapid evolution of resistance. Hence, our goal is to overcome
this resistance mechanism by designing and developing novel Enzalutamide analogues. We designed a dataset of
Enzalutamide derivatives using Enzalutamide's shape and electrostatic features to match with pharmacophoric
features essential for tight binding with the androgen receptor. Based on this design strategy ten novel derivatives
were selected including 5,5-dimethyl-3-(6-substituted benzo[d]thia/oxazol-2-yl)-2-thioxo-1-(4-(trifluoromethyl)
pyridin-2-yl)imidazolidin-4-one (6a-j) for synthesis. All the compounds were evaluated in-vitro on prostate can-
cer cell lines DU-145, LNCaP and PC3. Interestingly, two compounds 3-(6-hydroxybenzo[d]thiazol-2-yl)-5,5-
dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl) imidazolidin-4-one (6c, IC50 – 18.26 to 20.31μM) and 3-(6-
hydroxybenzo[d]oxazol-2-yl)-5,5-dimethyl -2-thioxo- 1- (4-(trifluoromethyl) pyridin-2-yl)imidazolidin-4-one (6h,
IC50 – 18.26 to 20.31μM) were successful with promising in-vitro antiproliferative activity against prostate cancer
cell lines. The binding mechanism of potential androgen receptor inhibitors was further studied by molecular
docking, molecular dynamics simulations and MM-GBSA binding free energy calculations and found in agreement
with the in vitro studies. It provided strong theoretical support to our hypothesis.1. Introduction
Prostate cancer is the cancer of prostate gland in the male repro-
ductive system, which is the secondmost frequent cancer in men and fifth
amongst all cancer mortality. According to the World Health Organiza-
tion report, in 2018, 1.28 million new prostate cancer cases were found
of 18.1 million cancer cases, worldwide [1]. Prostate cancer is generally
observed in older age patients with asymptomatic during the early stage.
Later, most common complaints are difficulty in urination, blood in urine
and pain in pelvis or back. Treatment strategies of prostate cancer are
based on lowering the male sex hormone levels called testosterone, as it
plays a central role in cancer growth. Testosterone level can be reduced
either by surgical castration [2] (removal of testicles) or by testosteroneBhole).
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Figure 1. Representative second-generation AR antagonists.
R.P. Bhole et al. Heliyon 7 (2021) e06227CRPC is the most aggressive and incurable form of prostate cancer
where the tumour keeps growing even with deficient testosterone in the
body. Recently developed next-generation AR antagonists (Figure 1)
Apalutamide (I), Enzalutamide (II) (FDA approved), Darolutamide (III)
and Proxalutamide (IV) (under clinical trials) increased the hopes of
overall survival for patients with CRPC [5].
Enzalutamide is the most promising option for treating deadly CRPS.
It is a nonsteroidal androgen receptor inhibitor with five to eight-fold
higher affinity than clinically used bicalutamide effective in metastatic
and non-metastatic CRPS [6]. Enzalutamide also impacts the nuclear
translocation of AR and prevents AR binding to deoxyribonucleic acid
(DNA) and co-activator proteins [7].However, current findings revealed
that the F876L mutation in AR leads to the genetic and phenotypic
changes indicating rapid evolution of drug resistance [8].Recently Bas-
setto et al., reported developing some novel bicalutamide and enzaluta-
mide derivatives as antiproliferative agents in treating prostate cancer.
Synthesised novel fluorinated analogues of bicalutamide and enzaluta-
mide and found a 50-fold improvement in the activity. These compounds
also showed a full AR antagonist effect. However, there are very few
research works published that address this problem. Hence, it's an urgent
and unmet need to overcome this resistance mechanism by designing and
developing novel Enzalutamide analogues to treat CRPC successfully.
Here, we demonstrated a hypothesis by designing a small dataset of
enzalutamide analogues by achieving 3D shape and electrostatic simi-
larity studies. Top ten Tanimoto scoring molecules as 5,5-dimethyl-3-(6--
substituted-benzo[d]thia/oxazol-2-yl)-2-thioxo-1-(4-(trifluoromethyl)
pyridin-2-yl)imidazolidin-4-ones (6a-j) were selected for synthesis and
evaluated in-vitro against prostate cancer cell lines DU-145, LNCaP and
PC3. Mechanism of active candidates was further studied by molecular
docking, molecular dynamics simulations and MM-GBSA binding free
energy calculations. In-silico results found to be in agreement with the in
vitro studies and provide insights for further exploration of active HITs.
2. Experimental
2.1. Design of novel AR antagonists
All the molecular docking studies were carried out on the Schrodinger
molecular modelling suite (Maestro, version 9.0 and 9.4) and academic
visualiser of Maestro 19.2, the modules used were Ligprep, Protein2
preparation wizard and Glide [9]. MD studies carried out on the pre and
post-synthetic modes. In the first step, all the molecules designed were
subjected to various confirmations and minimisation of energies, done
using the Limper module; it optimises all the energies and provides all
possible confirmations for a particular molecule. These are stored in the
module's worktable and subjected to docking.
The protein structure (PDB: 3V49) contains cofactors, water mole-
cules and several other groups needed to form a crystal. In protein
preparation, water molecules and ions were removed using the protein
preparation wizard [10]. The grid was generated using the receptor grid
generation panel. The molecular docking was carried out with a Glide
module of software; compounds were docked on the prepared protein.
All the simulations were done on the OPLS5.0 force field with the mol-
ecules flexible and ten conformations allowed each molecule in the
standard precision (XP) mode. The AR crystal structure (PDB 3V49) was
employed as the receptor with compounds 6a-j as ligands.14The results
obtained in the form of dock score representing the minimum energies,
the interaction between the ligand and the respective residues also pre-
sented. H-bond, van der Waals forces reported as well.
3. Material and methods
3.1. General
The chemicals and solvents used in this work obtained from Alfa
Aeser, UK and Sigma Aldrich, USA. Melting points (mp) for all the
compounds was carried out within open capillaries using Theil's tube
melting-point device and recorded uncorrected. IR spectra (KBr) were
developed and created on JASCO FT/IR-4000 spectrophotometer (Jasco,
USA). 1H spectra were obtained from a Bruker Advance-II 400 Spec-
trometer on 400 MHz using tetramethylsilane (TMS) as the internal
standard. The chemical shift values for all the synthetic derivatives
recorded as δ (parts per million). Coupling constant value J measured in
hertz. The peaks are presented as s ¼ singlet, d ¼ doublet, t ¼ triplet, dd
¼ double doublet, m ¼ multiple. TLC method used to determine the
purity of compounds using Merck, silica gel, HF254–361, type 6, 0.25
mm. Electron Spray Ionization Mass Spectrometry recorded on Waters
HPLC system with Q-Time of Flight LC-MS spectrometry (Waters-
Micromass LC-MS, US).
R.P. Bhole et al. Heliyon 7 (2021) e062273.2. Molecular modelling studies
Crystal structures from the Research Collaboratory for Structural
Bioinformatics Protein Data Bank (RCSB-PDB) selected for molecular
docking study. Androgen receptor crystal structure (PDB ID: 3V49) was
chosen; as this crystal structure have a known active site with bound
Enzalutamide [11].The protein preparation wizard of Schr€odinger
maestro v9.0 was used to prepare the receptor protein by adding
hydrogen, treating metal, deleting water molecules and assigning par-
tial charges by using the OPLS-2005 force field, then setting proton-
ation states and determining restrained and further partial energy
minimised with 0.3Å RMSD limit. The binding site was defined by
referring the ligand then grid generated using a grid box volume of
20_20_20 Å. The shape similarity analysis was also carried out and
results were shown in Table 1.
The dataset of ten experimental compounds, enzalutamide (ENZ),
bicalutamide (BIC) with their possible conformations were exported in
Schrodinger Maestro v9.0 (Schr€odinger, Inc., New York, NY). Each
structure subsequently processed with the LigPrep v2.3 (Schr€odinger,
Inc., New York, NY) to assign protonation states appropriate for
physiological pH, using the "ioniser" subprogram. Ligand structures
obtained from the LigPrep run used for generating 32 ligand confor-
mations using the default parameters of mixed torsional/Low-mode
sampling function.
Molecular docking performed by extra precision (XP) method using
the Glide module of the Schrodinger Suite. The lowest energy binding
pose of each docked ligand retained. The docking experiment results
were analysed using glide XP visualiser, and the crucial active site in-
teractions recorded along with the scoring functions.
All ten ligands, ENZ and BIC, docked complexes simulated using
AMBER18 package [12, 13] Topology and coordinate parameters for
androgen receptor generated with an AMBER99SB force field. The li-
gands were parametrised with a general amber force field (GAFF)in the
xLeap module. The ligand parametrisation performed with ANTE-
CHAMBR [14] program in the AMBER18package. The protein-ligand
complexes embedded in the TIP3P water model with a margin of 1.0
nm in a periodic cubic box [15]. The system was neutralised to pH seven
by adding counter ions. Added a sufficient number of ions to obtain the
salt concentration of 1.5 M. All the bond lengths were constrained using
the SHAKE algorithm, and electrostatic interactions were calculated by
the Particle Mesh Ewald (PME) method. The solvated system was sub-
jected to energy minimisation using the steepest descent algorithm to
eliminate bad contacts with added water molecules until a series of
equilibration protocol reached a tolerance of 1000 kJ mol-1. The system
was further treated for equilibration by five ns NVT simulation at 300 K,
followed by five ns of NPT simulation to achieve the simulated system's
proper equilibration. Final production simulations were performed in the
isothermal isobaric (NPT) ensemble at 300 K, using an external bath with
a coupling constant of 0.1 ps, the total simulation time achieved was 100
ns. Using pressure coupling pressure was kept constant (1 bar) with the
time constant to 1 ps. The trajectories stored at every two ps during the
simulation and trajectories analysed using built-in commands of
AMBER18. Trajectories of docked complexes used to calculate binding
energies using Van der Waal, electrostatic, polar solvation, SASA, and
Schrodinger binding and docking with protein carried out using Glide
docking module. The molecular mechanics generalised Born surface area
(MM-GBSA) method AMBER18 was used to measure the receptor and
ligands' binding strength quantitatively [16]. The average interaction
energies of all the ten compounds, BIC and ENZ, was calculated for 100
ns of MD trajectories [13].
3.3. Chemistry
To obtain the final products compounds 6a-j, the four-step synthetic
protocol was followed, initially compound 2a-j were prepared from3
compounds 1a-j. Simultaneously, compound 3, 4 were synthesised and
finally in the cyclisation step final derivatives 6a-j were synthesised and
characterised. Detailed Synthesis is discussed below as follows; Proced-
ure for Synthesis of 2-isothiocyanato-6-substituted benzo[d]thiazole
2a-j.
Substituted 2-amino benzothiazoles/benzoxazoles1a-j (1.0 mmol)
were added to a mixture of DMF (5 mL) & NaHCO3 (0.82 g) in water (5
mL), the resultant solution was cooled to -5 C, to this cold solution
thiophosgene (3.8 mmol) was added dropwise with stirring, the addition
was completed in 10 min, after that the mixture was stirred overnight.
The resulting mixture was extracted with DCM (20 mL x 2) and wash
with a solution of NaCl (Saturated); the organic layer was separated and
dried over Na2SO4 and concentrated under vacuum to obtain the
products.
3.3.1. Procedure for Synthesis of 2-methyl-2-(4-(trifluoromethyl)pyridin-2-
ylamino) propanoic acid 4
2-Bromo-4-(trifluoromethyl)pyridine3 (5.95 mmol) was added to a
blend of DMF: Water (9:1) (10 mL), this solution was added to a mixture
of K2CO3 (18.0mmol), CuCl (1.5 mmol) and 2-aminoisobutyric acid (10.0
mmol). The reaction mixture was warmed to 30 C, and then 2-acetylcy-
cloheanone (1.40 mmol) was added. The reaction mixture was stirred
overnight at 120 C. On cooling, the reaction mixture was extracted with
water (20  2 mL) and ethyl acetate (20  2 mL). The organic solvent
was dried over Na2SO4 and concentrated under vacuum to obtain com-
pound 4.
3.3.2. Procedure for Synthesis of methyl 2-methyl-2-(4-(trifluoromethyl)
pyridin-2-ylamino)propanoate 5
A mixture of 4 (10 mmol) in a solution of K2CO3 (8.5 mmol) and
DMF:Water (7:3) (10 mL) was warmed to 30 C. To this mixture Iodo-
methane (10 mmol) was added and heated to 40 C for 2–3 h. To this
solution, dilute acetic acid (0.144 mL) was added. The reaction mixture
was allowed to cool and extracted with DCM (20  2 mL), dried over
Na2SO4. The organic layer was concentrated under vacuum to provide
with the product in quantitative yield.
3.3.3. Procedure for Synthesis of 5,5-dimethyl-3-(6-methylbenzo[d]thiazol-
2-yl)-2-thioxo-1- (4-(trifluoromethyl) pyridin-2-yl)imidazolidin-4-one 6a
A mixture of 2a (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with EtOAc and
washed with brine. The organic layer was dried over MgSO4 and
concentrated under vacuum to obtain the final derivative as 6a.
Mp:256–258 C; 1H NMR (CDCl3): δ 1.34 (s, 6H, CH3), 2.36 (s, 3H,
CH3), 6.62 (m, 1H, Ar–H), 6.7 (d, 1H, J¼ 6.8, Ar–H), 7.35 (m, 1H, Ar–H),
7.92 (s, 1H, Ar–H), 8.11 (s, 2H, Ar–H);13C-NMR (CDCl3): δ 177.0, 171.4,
160.0, 155.5, 153.2, 150.2, 147.3,134.1, 148.8, 130.7, 126.6, 123.6,
121.3, 117.7, 123.6, 124.1, 112.7, 23.4(2); Anal. Calcd for
C19H15F3N4OS2: C, 52.28; H, 3.46; F, 13.06; N, 12.84; O, 3.67; S, 14.69;
MS (ESI) m/z:436.0639.
3.3.4. Procedure for Synthesis of 3-(6-methoxybenzo[d]thiazol-2-yl)-5,5-
dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6b
A mixture of 2b (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with EtOAc and
washedwith a concentrated solution of NaCl. The organic layer was dried
over MgSO4 and concentrated under vacuum to obtain the final deriva-
tive as 6b.
Mp: 259–261 C; 1H-NMR (CDCl3): δ 1.37 (s, 6H, CH3), 3.73 (s, 3H,
O–CH3), 6.67 (m, 1H, Ar–H), 6.86 (d, 1H, J ¼ 6.87, Ar–H), 7.19 (m, 1H,
Ar–H), 7.56 (s, 1H, Ar–H), 8.15 (s, 2H, Ar–H); 13C-NMR (CDCl3): δ 160.0,
171.4, 177.0, 145.5, 78.4, 156.7, 153.2, 147.3, 104.9, 118.2, 148.8,
112.7, 114.6, 117.7, 124.1, 55.8, 23.1(2); Anal. Calcd for
Table 1. The ROCS Tanimoto shape similarity coefficient (TSSC), Tanimotocolor similarity coefficient (TCSC) and Tanimoto combine (TC) of compounds 6a-6j with
respect to the structure of Enzalutamide.
Data set 6a 6b 6c 6d 6e 6f 6g 6h 6i 6j
TSSC 0.669 0.572 0.676 0.567 0.58 0.587 0.671 0.671 0.646 0.677
TCSC 0.413 0.434 0.404 0.354 0.413 0.407 0.381 0.381 0.362 0.408
TC 1.082 1.007 1.08 0.92 0.993 0.994 1.052 1.052 1.008 1.084
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MS (ESI) m/z:452.0589.
3.3.5. Procedure for Synthesis of 3-(6-hydroxybenzo[d]thiazol-2-yl)-5,5-
dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6c
A mixture of 2c (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was extracted with EtOAc and brine. The
isolated organic layer was dried over MgSO4 and concentrated under
vacuum to obtain the final derivative as 6c.
Mp: 239–241 C; 1H-NMR (CDCl3): δ 1.24 (s, 6H, CH3), 6.5 (m, 1H,
Ar–H), 6.76 (d, 1H, J ¼ 6.82, Ar–H), 7.20 (m, 1H, Ar–H), 7.74 (s, 1H,
Ar–H), 8.01 (s, 2H, Ar–H), 11.3 (s, 1H, Ar-OH);13C-NMR (CDCl3): δ
160.0, 132.3, 171.4, 177.0, 145.8, 78.4, 155.1, 153.2, 147.3, 106.5,
117.9, 148.8, 112.7, 114.9, 117.7, 124.1, 23.7(2); Anal. Calcd for
C18H13F3N4O2S2: C, 49.31; H, 2.99; F, 13.00; N, 12.78; O, 7.30; S, 14.63;
MS (ESI) m/z:438.0432.
3.3.6. Procedure for Synthesis of 5,5-dimethyl-3-(6-nitrobenzo[d]thiazol-2-
yl)-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6d
A mixture of 2d (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction solvent system was then extracted dichloro
methane and washed with brine. The DCM layer was dried over MgSO4
and concentrated under vacuum to obtain the final derivative as 6d.
Mp:289–290 C; 1H-NMR (CDCl3): δ 1.73 (s, 6H, CH3), 6.7 (m, 1H,
Ar–H), 6.82 (d, 1H, J ¼ 6.85, Ar–H), 7.22 (m, 1H, Ar–H), 7.73 (s, 1H,Figure 2. Structural feature and overlay study of Enzaluta
Table 2. Antiproliferative activity of novel Enzalutamide analogues (6a - 6j).














Ar–H), 8.19 (s, 2H, Ar–H);13C-NMR (CDCl3): δ 160.6, 131.3, 171.4,
177.0, 159.3, 78.4, 153.2, 147.3, 144.3, 119.1, 117.3, 148.8, 112.7,
121.3, 118.7, 124.3(2); Anal. Calcd for C18H12F3N5O3S2:C, 46.25; H,
2.59; F, 12.19; N, 14.98; O, 10.27; S, 13.72; MS (ESI) m/z:467.0334.
3.3.7. Procedure for Synthesis of 3-(6-chlorobenzo[d]thiazol-2-yl)-5,5-
dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6e
A mixture of 2e (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with dichlro methane
(DCM) and washed with salt water. The organic layer was dried over
magnesium sulfate and concentrated under vacuo to obtain the final
derivative as 6e.
Mp: 250–252 C; 1H-NMR (CDCl3): δ 1.72 (s, 6H, CH3), 6.3 (m, 1H,
Ar–H), 6.43 (d, 1H, J¼ 6.80, Ar–H), 6.9 (m, 1H, Ar–H), 7.11 (s, 1H, Ar–H),
7.92 (s, 2H, Ar–H);13C-NMR (CDCl3): δ 163.1, 132.3, 171.4, 177.3, 151.3,
78.4, 129.8, 153.2, 147.3, 121.2, 118.3, 148.8, 112.7, 125.8, 117.7,
124.1, 23.1(2); Anal. Calcd for C18H12ClF3N4OS2: C, 47.32; H, 2.65; Cl,
7.76; F, 12.47; N, 12.26; O, 3.50; S, 14.04; MS (ESI) m/z:456.0093.
3.3.8. Procedure for Synthesis of 5,5-dimethyl-3-(6-methylbenzo[d]oxazol-
2-yl)-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6f
A mixture of 2f (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with DCM and washed
with brine. The DCM layer was dried over sodium sulphate and














Figure 3. (a) Shape and (b) electrostatic features of ENZ (II). (c) Overlay of the designed compound with ENZ (II) showing similar shape and volume. (d) The
electrostatic similarity of the designed compound with ENZ (II).\
R.P. Bhole et al. Heliyon 7 (2021) e06227Mp: 234–236 C; 1H-NMR (CDCl3): δ 1.35 (s, 6H, CH3), 2.39 (s, 3H,
CH3), 6.60 (m, 1H, Ar–H), 6.73 (d, 1H, J ¼ 6.1, Ar–H), 7.32 (m, 1H,
Ar–H), 7.91 (s, 1H, Ar–H), 8.15 (s, 2H, Ar–H); 13C-NMR (CDCl3): δ 171.4,
152.6, 149.9, 177.0, 165.6, 78.4, 153.2, 147.3, 111.5, 119.0, 132.2,
148.8, 112.7, 123.6, 126.7, 117.7, 124.1, 23.4(2); Anal. Calcd for
C19H15F3N4O2S: C, 54.28; H, 3.60; F, 13.56; N, 13.33; O, 7.61; S, 7.63;
MS (ESI) m/z:420.0868.
3.3.9. Procedure for Synthesis of 3-(6-methoxybenzo[d]oxazol-2-yl)-5,5-
dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6g
A mixture of 2g (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with ethyl acetate and
washed with brine. The organic layer was dried over MgSO4 and
concentrated under vacuum to obtain the final derivative as 6g.
Mp: 241–243 C; 1H-NMR (CDCl3): δ 1.32 (s, 6H, CH3), 3.78 (s, 3H,
O–CH3), 6.66 (m, 1H, Ar–H), 6.86 (d, 1H, J ¼ 6.80, Ar–H), 7.22 (m, 1H,
Ar–H), 7.55 (s, 1H, Ar–H), 8.01 (s, 2H, Ar–H); 13C-NMR (CDCl3): δ 171.4,
152.6, 149.9, 177.0, 140.6, 78.4, 147.3, 111.5, 119.0, 132.2, 148.8,Scheme 1. Synthetic scheme for 6a-6j; Reagents and conditions: (a) Thiophosgene,
2-acetylcyclohexanone; (c) Methyl iodide, K2CO3; c) Thiophosgene, Sodium hydro
acetoxypropane.
5
112.7, 126.7, 117.7, 124.1, 23.3(2), 21.6; Anal. Calcd for
C19H15F3N4O3S: C, 52.29; H, 3.46; F, 13.06; N, 12.84; O, 11.00; S, 7.35;
MS (ESI) m/z:436.0817.
3.3.10. Procedure for Synthesis of 3-(6-hydroxybenzo[d]oxazol-2-yl)-5,5-
dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6h
A mixture of 2h (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with DCM and washed
with brine. The organic layer was dried over Na2SO4 and concentrated
under vacuum to obtain the final derivative as 6h.
Mp: 237–238 C; 1H-NMR (CDCl3): δ 1.22 (s, 6H, CH3), 6.52 (m, 1H,
Ar–H), 6.77 (d, 1H, J ¼ 6.88, Ar–H), 7.22 (m, 1H, Ar–H), 7.73 (s, 1H,
Ar–H), 8.05 (s, 2H, Ar–H), 11.1 (s, 1H, Ar-OH); 13C-NMR (CDCl3): δ
171.4, 152.6, 151.4, 177.0, 136.2, 78.4, 153.2 (2),147.3, 98.0, 120.5,
148.8, 112.7, 116.3, 117.7, 124.1, 23.1(2); Anal. Calcd for
C18H13F3N4O3S: C, 51.18; H, 3.10; F, 13.49; N, 13.26; O, 11.36; S, 7.59;
MS (ESI) m/z:422.0660.NaHCO3; d) DMSO, 2-acetoxypropane. (b) 2-aminoisobutyric acid, K2CO3, CuCl,
gen carbonate, H2O, Dichloro methane, RT, 24 h; d) Dimethyl Sulphoxide, 2-
R.P. Bhole et al. Heliyon 7 (2021) e062273.3.11. Procedure for Synthesis of 5,5-dimethyl-3-(6-nitrobenzo[d]oxazol-
2-yl)-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6i
A mixture of 2i (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with EtOAc and
washed with brine. The acetate layer was dried over MgSO4 and
concentrated under vacuum to obtain the final derivative as 6i.
Mp: 279–281 C; 1H-NMR (CDCl3): δ 1.72 (s, 6H, CH3), 6.69 (m, 1H,
Ar–H), 6.80 (d, 1H, J ¼ 6.84, Ar–H), 7.20 (m, 1H, Ar–H), 7.71 (s, 1H,
Ar–H), 8.12 (s, 2H, Ar–H); 13C-NMR (CDCl3): δ 171.8, 152.6, 147.2,
177.0, 149.7, 78.4, 147.7,144.2, 104.5, 114.1, 148.8, 112.7, 121.3,
117.7, 124.1, 23.9(2); Anal. Calcd for C18H12F3N5O4S: C, 47.90; H, 2.68;
F, 12.63; N, 15.52; O, 14.18; S, 7.10; MS (ESI) m/z:451.0562.
3.3.12. Procedure for Synthesis of 3-(6-chlorobenzo[d]oxazol-2-yl)-5,5-
dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one 6jA mixture of 2j (2.0 mmol) and 5 (2.0 mmol) was dissolved in a
mixture of DMSO: Isopropyl acetate (1:2) (10 mL) and stirred overnight
at 84 C. The reaction mixture was then extracted with DCM and washed
with brine. The organic layer was dried over Na2SO4 and concentrated
under vacuum to obtain the final derivative as 6j.
Mp: 231–233 C; 1H-NMR (CDCl3): δ 1.71 (s, 6H, CH3), 6.33 (m, 1H,
Ar–H), 6.44 (d, 1H, J ¼ 7.11, Ar–H), 6.89 (m, 1H, Ar–H), 7.01 (s, 1H,
Ar–H), 7.90 (s, 2H, Ar–H); 13C-NMR (CDCl3): δ 171.4, 152.6, 151.4,
177.0, 141.7, 78.4, 127.2, 153.2, 147.3, 111.2, 121.5, 148.8, 112.3,
123.7, 118.7, 124.1, 23.7(2); Anal. Calcd for C18H12ClF3N4O2S: C, 49.04;




3.4.1.1. Cell culture. All the three cell lines were obtained from the
ATCC, USA; DU145, LNCaP and PC-3 and were preserved suitably, these
were further cultured in the Dulbecco's Eagle medium modified to
contain supplements like the fetal Bovine Serum (10%) with penicillin
(100 U/mL) and Streptomycin (0.1 mg/mL). These were incubated under
5 % CO2 at humid conditions with 37 C temperature.
3.4.1.2. Antiproliferative assay by Oncotest method. The imidazolidinones
were assayed for their antiproliferative activity by the Oncotest's
monolayer method developed earlier by Maier et. al [17]. against the
prostate cancer cell lines. Enzalutamide employed as a standard drug.
This assay is based on the propodeum iodide method and the compounds
observed after four days of treatment. The results are presented by
nonlinear regression analysis as IC50 in Table 2. All the ten derivative 6a-j
were evaluated at ten dilutions with a half-log increase up to the 100 1M
in triplicates [18, 19, 20, 21, 22, 23, 24].
3.4.1.3. Oncotest protocol and its modifications. A modified Propidium
Iodideassay was used to assess the effect of the test compound on the
growth of the three human tumor cell lines. Cells were plated in 96-well
flat-bottom microtiter plates at a cell density of 4000–20 000 cells per
well. After a24 h recovery period to allow the cells to resume exponential
growth the compounds were applied at 10 concentrations in half-
logincrements in triplicates and treatment continued for 4 days. After 4
days of treatment, cells were next washed with 200 ml phosphate-
buffered solution to remove dead cells, then 200 ml of a solution con-
taining 7 mg/ml propidiumiodide and 0.1%(v/v) Triton X-100 were
added to the wells. After an incubation period of 1–2 h at room tem-
perature, fluorescence was measured using the Cytofluor 4000 micro-
plate reader (Millipore, Schwalbach, Germany) (excitation l¼530 nm,
emission l¼620 nm) to quantify the amount of attached viable cells.6
Pharmacological effects on cell proliferation and survival were expressed
as Test/Control_100 (%T/C) values. On the basis of the T/C values,
relative IC50 values were determined by non-linearregression (log[conc.
of inhibitor] versus response (% T/C)) using the Graph Pad Prism anal-
ysis software. For calculation of mean IC50 values over the 3 cell lines as
tested, the geometric mean was selected.
4. Results and discussion
4.1. Design of novel AR antagonists
2-Thioxo-5,5-dimethyl-imidazolidin-4-one is the common struc-
tural scaffold found as a core in known FDA approved AR antagonists
Apalutamide (I) [18] and Enzalutamide (II) [19]. Keeping in mind the
common structural scaffold, ten analogue molecules with structural
features similar to reference compounds were designed. The central
core was preserved, but the side arms were replaced with benzox-
azole/benzothiazole and trifluoromethyl pyridine [20].Shape and
electrostatic similarities of designed molecules were achieved to be
similar to the ENZ (Table 1 and Figure 2c). We hypothesise that
three-dimensional molecular shape and electrostatic features deter-
mine recognition by enzyme/receptor active site, contributing exten-
sively to its binding affinity. Tanimoto shape similarity coefficient
(TSSC) and Tanimotocolour similarity coefficient (TCSC) scores in the
range of 0–1 were used to quantitatively compare and rank the sim-
ilarity of shape and electrostatic features of designed molecules
[21].Here, value of 1 indicates complete similarity and 0 indicates no
similarity of shape (TSSC) and atom type (TCSC). The tanimoto combo
(TC) is the sum of TSSC and TCSC. Indicates that the designed mol-
ecules having 0.57 to 0.68 TSSC score i.e. 57%–68% 3D shape simi-
larity and 0.35 to 0.43 TCSC score i.e 35%–43% colour (atom to atom)
similarity with Enzalutamide.
As shown in Figure 3a, c, designed molecule occupies the same
shape and volume of Enzalutamide. Whereas, Figure 3b, representing
pharmacophoric features of Enzalutamide like hydrogen bond donor
(blue), hydrogen bond acceptor (red), ring (green) and hydrophobic
region (yellow). Interestingly, ROCS studies demonstrate that the
designed molecule features also match with these pharmacophoric re-
quirements (Figure 3d). Benzoxazole/benzothiazole molecule overlaps
with ring (green) and hydrogen bond acceptor region (red) [20].
However, trifluoromethyl pyridine overlay with ring (green) region but





j) are described in Scheme 1. 2-isothiocyanato-6-susbstituted benzo[d]
thiazole/benzo[d]oxazole (2a-2j) were prepared by reacting 2-amino-
benzo[d]thiazole/benzo[d]oxazole with thiophosgene. Simultaneously,
2-methyl-2-(4-(trifluoromethyl)pyridin-2-ylamino)propanoate (5) was
synthesized in two steps as follows, in first step, 2-Bromo-4-(trifluoro-
methyl)pyridine (3) reacted with 2-aminoisobutyric acid in presence of
K2CO3 and CuCl to get 2-methyl-2-(4-(trifluoromethyl)pyridin-2-yla-
mino) propanoic acid (4). Then in the second step, product 4 was reac-
ted with methyl iodide in presence of K2CO3 to obtain 2-methyl-2-(4-
(trifluoromethyl)pyridin-2-ylamino)propanoate (5). While, in the last




In-vitro evaluation for determining the efficacy of novel Enzalutamide
analogues (6a - 6j) against three different prostate cancer cell lines like
Figure 4. Antiproliferative activity of novel Enzalutamide analogues (6a - 6j).
R.P. Bhole et al. Heliyon 7 (2021) e06227DU-145, LNCaP and PC-3 were carried out. The results (Table 2)
demonstrate that compound 6c and 6h are potent antiproliferative
molecules. Compound 6c shows IC50 values of 20.31, 19.21 and 18.36
μM, whereas, compound 6h had IC50 of about 16.50, 22.41 and 20.44 μM
for the cell lines DU145, LNCaP and PC-3 respectively. The anti-
proliferative activity of these compounds was promising compared to the
standard drug (Enzalutamide, IC50 ¼ 28.20, 31.78 and 27.32 μM against
the cell lines DU-145, LNCaP and PC 3 respectively). This in-vitro anti-
proliferative activity is also supported by the theoretical studies of
binding affinity based on dock score of design molecules. It was found
that two compounds, 6c (Dock score ¼ -8.49) and 6h (Dock score ¼
-8.46) exhibited similar binding affinity with the AR compared to the
standard drug (Enzalutamide, Dock score ¼ -10.49).
4.4. Molecular modelling studies
Molecular docking studies were performed with Schrodinger molec-
ular modelling suite in the XP mode [22]. It demonstrated that designed
molecules occupy similar pose and interactions similar to ENZ in the
active site of AR earlier.
The drug molecule enzalutamide and its newly synthesised analogues
were analysed initially by molecular docking studies. Then these mole-
cules were subjected to the molecular dynamic simulations followed by
MMGBSA calculations. The bicalutamide and enzalutamide are known as
AR inhibitors. We designed and synthesised a series on analogues of these
drugs. The compounds 6c and 6h have shown comparative activity in in
vitro assays (Figure 4a). Compounds bicalutamide and enzalutamide are
structural analogues, enzulatamide having a glycolyl thiourea nucleus
similar to the test compounds; hence docking and molecular dynamics
simulation for both drug molecules was performed. Docking of bicalu-
tamide to the AR shows that; the drug molecule occupies the active site
and interacts with the Trp741 and Leu876, which is similar to its inter-
action in the crystal structure (2AXA). Similarly, enzalutamide docks in
AR (3V49) active site, and forms interactions with the residues Arg751
and His874 (Figure 5b, c).
To further evaluate the compounds, molecular dynamics studies
performed in AMBER18 molecular modelling suite. The docked com-
plexes, ligand 6a-j, bicalutamide (BIC) and enzalutamide (ENZ) were
validated to bind with the AR for 100 ns. The compounds were found
to be stable throughout the simulation (Figure 6). ENZ, 6c and 6h were
found to be stable during the period of simulation with slight variation7
in RMSD between 70 to 90 ns; Compound 6c fluctuated between 15 to
45 ns and after that equilibrated to 1.5 Å, Compound 6h showed the
RMSD between 1-2 Å for first 40 ns and later equilibrated to about 2 Å
after 70 ns (Figure 7a). Figure 7b shows the superposition of ligands
obtained from docking studies before the MDS. Rest of the ligands
were also stable throughout the MD simulation with slight fluctuations
between 70 to 90 ns (Figure 6). The structural changes were visibly
studied, the docked complexes retained their position in all the cases,
which is evident from their superposed structures before and after MDS
(Figure 7). Compounds bound to the AR receptor crystal structure
2AXA retained their interactions with residues Trp741 and Leu876
(Figure 7b, c). In AR receptor crystal structure 3V49, the compounds 6c
and 6h retained their interaction with the active site residues, Arg752
and His 874 (Figure 7e, f). The MM-PBSA/GBSA is a widely accepted
tool for calculating the binding free energies of the biomolecular
complexes. We performed these calculations to ascertain the interac-
tion energies and stability of our ligand-protein complexes. AR-ENZ
and AR-BIC were also studied along with the rest of the ten com-
plexes as a measure of control. In this study, we selected all the 10000
frames from the MD trajectory. The binding energy and its components
were obtained by the MM-GBSA methods for compounds ENZ, BIC, 6c
and 6h are listed in Table 3; the rest of the information is provided in
SI_table-1 [23].The individual components of the binding free energy
calculations are van der Wall forces (vdW), electrostatic energy (EEL)
as calculated by the MM force field, the electrostatic contribution to
the solvation free energy calculated by GB (EGB), the electrostatic
contribution to the solvation free energy calculated by PB (EPB) and
Nonpolar solvation energy for GB and PB respectively (ENPOLAR) and
nonpolar contribution to the solvation free energy (ESURF). As shown
in Table 4, the compounds ENZ, 6c and 6h showed ΔGbindvalues,
-50.97, -35.23 and -35.74 kcal/mol1 and -8 kcal/mol1 respectively;
indicates that ENZ has higher binding free energy, but compounds 6ca
and 6h have comparable binding energies. In the docked complexes
with AR crystal structure bound to Compound BIC, 6c and 6d showed
binding energy of -45.11, -30.50 and -35.11 kcal/mol1 respectively. In
both cases, the van der Waal's contribution was high mainly due to the
Ligand-protein complex's hydrophobic regions. The free energy calcu-
lations These results of binding free energy indicate that newly syn-
thesised molecules do have good binding affinity to the AR but
compared to the standard drug, they need further modifications to
improve their binding efficiency.
Figure 5. Molecular docking and dynamics
simulations predict a novel binding mode for
benzazole derivatives. (A) Structures of the
anti-androgens bicalutamide (first from top),
enzalutamide (second from top), and 6c and
6h oriented to highlight the molecules'
common and discrete regions. The A-C
annotation of the rings is indicated; (B)A
magnified view of the docked structure of
bicalutamide (green) in AR (PDB: 2AXA); (C)
A magnified view of the docked structure of
enzalutamide (green) in AR (PDB: 3V49).
Figure 6. (A) Root mean square deviation (RMSD) in MDS for enzalutamide (ENZ), compound 6c and 6h. (B) The superposed structure obtained after molecular
docking studies for ENZ-6c and ENZ-6h respectively.
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Figure 7. Molecular docking and dynamics simulations predict a novel binding mode for benzazole derivatives. (A) Bicalutamide cocrystal structure (green) in AR
(PDB: 2AXA), magenta and purple are the initial and final conformation after molecular dynamics simulation for 100 ns; (B) Compound 6c in complex with the AR in
bicalutamide binding site, initial conformation (Cyan) and final conformation (dark blue) during the 100ns molecular dynamics simulation; (C) Compound 6h in
complex with the AR in bicalutamide binding site, initial conformation (yellow) and final conformation (dark green) during the 100ns molecular dynamics simulation;
(D) Enzalutamide cocrystal structure (green) in AR (PDB: 3V49) magenta and purple are the initial and final conformation after molecular dynamics simulation for 100
ns; (E) Compound 6c in complex with the AR in enzalutamide binding site, initial conformation (Cyan) and final conformation (dark blue) during the 100ns molecular
dynamics simulation; (F) Compound 6h in complex with the AR in enzalutamide binding site, initial conformation (yellow) and final conformation (dark green) during
the 100ns molecular dynamics simulation.
Table 3. Binding free energy components for the protein-ligand complexes calculated by MM-GBSA analysis, all energies are in Kcal/mol with standard deviation in
parenthesis.
Sr. No. 3V49 2AXA
Enzalutamide 6c 6h Bicalutamide 6c 6h
MM/GBSA
ΔEVDW -62.90 (2.8) -58.20 (2.4) -58.44 (2.6) -53.33 (2.6) -54.52 (2.6) -56.16 (2.7)
ΔEELE -19.98 (5.0) -15.76 (2.8) -14.66 (3.0) -32.68 (6.0) -15.81 (3.1) -20.42 (3.2)
ΔGGB 37.73 (3.4) 36.45 (2.4) 35.20 (2.6) 46.60 (5.3) 37.39 (2.7) 40.82 (2.5)
ΔGSurf -8.18 (0.1) -7.59 (0.1) -7.55 (0.1) -7.76 (0.1) -6.73 (0.1) -6.88 (0.1)
ΔGbind -50.97 (3.2) -35.23 (2.8) -35.74 (3.0) -45.11 (3.0) -30.50 (2.8) -35.11 (2.8)
Dock Score (Glide Score) -10.49 -8.49 -8.46 -8.42 -7.50 -6.97
ΔEVDW ¼ van der Waals contribution from MM; ΔEELE ¼ electrostatic energy as calculated by the MM force field; ΔGGB ¼ the electrostatic contribution to the solvation
free energy calculated by GB; ΔGSurf ¼ solvent-accessible surface area; ΔGSol ¼ solvation free energy; ΔGgas ¼ gas phase interaction energy; ΔGbind ¼ Binding free
energy [12].
R.P. Bhole et al. Heliyon 7 (2021) e062275. Conclusion
The quest of novel AR antagonist for the treatment of CRPC led to the
design of novel molecules based on the shape and electrostatic similarity9
with Enzalutamide. ROCS results showed that the designed molecules
have 58%–67% 3D shape similarity with Enzalutamide wherein com-
pounds 6c and 6h showed highest TSSC scores (0.67). The in-vitro
evaluation demonstrates that the compound 6c and 6h are promising
Table 4. Structural series of novel enzalutamide analogues.
Comp. no. 6a 6b 6c 6d 6e 6f 6g 6h 6i 6j
X S S S S S O O O O O
R1 CH3 OCH3 OH NO2 Cl CH3 OCH3 OH NO2 Cl
R.P. Bhole et al. Heliyon 7 (2021) e06227antiproliferative agents with IC50 20.31 μM, 19.21 μM and 18.36 μM
whereas, compound 6h showed IC50 of 16.50 μM, 22.41 μM and 20.44
μM against DU-145, LNCaP and PC-3 prostate cancer cell lines respec-
tively. It is remarkable that the novel compounds discovered in this study
(6c and 6h) are showing better in-vitro antiproliferative activity against
prostate cancer cell lines compared to the standard compound (Enzalu-
tamide) despite the less binding affinity. Also, the molecular docking,
molecular dynamics and free energy calculations suggest the stability of
the protein-ligand complex, which also indicates the affinity of the
molecules to the receptor and comparable biological activity.
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